Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm, Open Label Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT07713459 is registered in ClinicalTrials.gov with Kure Cells, INC as lead sponsor.

NCT NCT07713459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07713459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm, Open Label Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Lead sponsor
Kure Cells, INC
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
November 30, 2029
Enrollment
105 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

car t cell therapy, diffuse large b cell lymphoma (dlbcl), follicular b-cell non-hodgkin's lymphoma, lymphoma nonhodgkin, marginal zone b cell lymphoma